Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical development approaches for one of the...

Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB) Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001 Cambridge, UK, May 30, 2024:...

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein...

Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesisRefined focus on neurodegenerative...